Combining conventional ultrasound and sonoelastography to predict axillary status after neoadjuvant chemotherapy for breast cancer
JX Huang, SY Lin, Y Ou, CG Shi, Y Zhong, MJ Wei… - European …, 2022 - Springer
Objective To determine the ability of conventional ultrasound (US) combined with shear
wave elastography (SWE) to reveal axillary status after neoadjuvant chemotherapy (NAC) in …
wave elastography (SWE) to reveal axillary status after neoadjuvant chemotherapy (NAC) in …
[HTML][HTML] Developments in the management of metastatic HER2-positive breast cancer: a review
J Lebert, EJ Lilly - Current Oncology, 2022 - mdpi.com
Approximately 20% of breast cancers overexpress human epidermal growth factor receptor
2 (HER2), providing an actionable target for many different therapies. In the metastatic …
2 (HER2), providing an actionable target for many different therapies. In the metastatic …
Immunogenic Nanovesicle‐Tandem‐Augmented Chemoimmunotherapy via Efficient Cancer‐Homing Delivery and Optimized Ordinal‐Interval Regime
M Sun, W Shi, Y Wu, Z He, J Sun, S Cai… - Advanced …, 2023 - Wiley Online Library
The strategy of combining immune checkpoint inhibitors (ICIs) with anthracycline is
recommended by clinical guidelines for the standard‐of‐care treatment of triple‐negative …
recommended by clinical guidelines for the standard‐of‐care treatment of triple‐negative …
Mammographic breast density, benign breast disease, and subsequent breast cancer risk in 3.9 million Korean women
Background Mammographic breast density and benign breast disease are strong risk factors
for breast cancer. Accordingly, women with both risk factors may have a markedly high risk …
for breast cancer. Accordingly, women with both risk factors may have a markedly high risk …
Clinical validation of endopredict in pre-menopausal women with ER-positive, HER2-negative primary breast cancer
A Constantinidou, Y Marcou, MS Toss, T Simmons… - Clinical Cancer …, 2022 - AACR
Abstract Purpose: The EndoPredict prognostic assay is validated to predict distant
recurrence and response to chemotherapy primarily in post-menopausal women with …
recurrence and response to chemotherapy primarily in post-menopausal women with …
[HTML][HTML] Mediator roles of social support and hope in the relationship between body image distress and resilience in breast cancer patients undergoing treatment: A …
HT Hsu, CH Juan, JL Chen, HF Hsieh - Frontiers in psychology, 2021 - frontiersin.org
Breast cancer and its treatment are particularly distressing for patients because of their
potential impacts on body image. The most difficult phase of cancer treatment is usually the …
potential impacts on body image. The most difficult phase of cancer treatment is usually the …
[HTML][HTML] Luteolin prevents cardiac dysfunction and improves the chemotherapeutic efficacy of doxorubicin in breast cancer
Y Shi, F Li, M Shen, C Sun, W Hao, C Wu… - Frontiers in …, 2021 - frontiersin.org
Background: Doxorubicin (Dox) is one of the most effective chemotherapy agents used in
the treatment of solid tumors and hematological malignancies. However, it causes dose …
the treatment of solid tumors and hematological malignancies. However, it causes dose …
[HTML][HTML] Deep learning with biopsy whole slide images for pretreatment prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer: A …
Introduction Predicting pathological complete response (pCR) for patients receiving
neoadjuvant chemotherapy (NAC) is crucial in establishing individualized treatment. Whole …
neoadjuvant chemotherapy (NAC) is crucial in establishing individualized treatment. Whole …
68Ga-labeled fibroblast activation protein inhibitor PET/CT for the early and late prediction of pathologic response to neoadjuvant chemotherapy in breast cancer …
L Chen, S Zheng, L Chen, S Xu, K Wu… - Journal of Nuclear …, 2023 - Soc Nuclear Med
68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT has demonstrated
promising clinical results, with a higher SUVmax and tumor-to-background ratio (TBR) in …
promising clinical results, with a higher SUVmax and tumor-to-background ratio (TBR) in …
[HTML][HTML] Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
Z Li, S Guo, H Xue, L Li, Y Guo, S Duan… - Frontiers in …, 2023 - frontiersin.org
Background: Clinical trials have shown that the use of trastuzumab deruxtecan (DS-8201)
alone is expected to provide novel therapeutic options for HER2-low/positive patients …
alone is expected to provide novel therapeutic options for HER2-low/positive patients …